Trellus Health Share Price. TRLS - Stock Quote, Charts, Trade History, Share Chat, Financials. Trellus Health Plc

Gold vs US Dollar

Home
Investing
Stocks
UK
LSE
Trellus Health Plc (TRLS)
Trellus Health Plc (TRLS) Share Price

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Trellus Health Plc	LSE:TRLS	London	Ordinary Share	GB00BNNFM402	ORD GBP0.0006

	Price Change	% Change	Share Price	Shares Traded	Last Trade
	0.00	0.0%	7.50	299	01:00:00

Bid Price		Offer Price	High Price	Low Price	Open Price
7.00		8.00	7.50	7.50	7.50

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Offices Of Medical Doctors	0.03	-5.90	-9.50	-	12.11

Last Trade Time	Trade Type	Trade Size	Trade Price	Currency
08:31:45	O	299	7.111	GBX

Related Shares
Smith & Nephew (SN.), Convatec (CTEC), Physiomics (PYC), Deepverge (DVRG)

Trellus Health (TRLS) Latest News

Trellus Health News

Date	Time	Source	Headline
26/5/2023	07:00	UKREG	Trellus Health PLC Posting of Annual Report and Notice of AGM
23/5/2023	11:47	ALNC	Trellus Health loss widens in 2022 as predicts "pivotal" 2023
23/5/2023	07:21	ALNC	*Trellus says USD19.1m cash at Dec 31 provides runway into at least 2025
23/5/2023	07:00	UKREG	Trellus Health PLC Final Results
28/4/2023	07:00	UKREG	Trellus Health PLC Notice of Results
06/3/2023	13:49	ALNC	IN BRIEF: Trellus Health expects yearly loss due to high expenses
06/3/2023	07:00	UKREG	Trellus Health PLC Trading Update
17/2/2023	13:29	ALNC	Trellus Health shares rise on irritable bowel syndrome product launch
17/2/2023	07:00	UKREG	Trellus Health PLC Launch of D2C IBS Offering
13/2/2023	10:51	ALNC	Trellus inflammatory bowel disease product offered via NY Medicaid

More Trellus Health News

Trellus Health Investors Trellus Health Takeover Rumours

Trellus Health (TRLS) Discussions and Chat

Trellus Health Forums and Chat

Date	Time	Title	Posts
14/5/2023	07:38	Trellus Health - Digital Health Solution for complex chronic conditions	278

Add a New Thread

Trellus Health (TRLS) Most Recent Trades

Trade Time	Trade Price	Trade Size	Trade Value	Trade Type
07:31:46	7.11	299	21.26	O

View all Trellus Health trades in real-time

Trellus Health (TRLS) Top Chat Posts

Top Posts
Posted at 25/4/2023 18:23 by idomeneo This might not be the bottom but I bought £5k here. There are lots of negatives, but there is time and cash (it qualifies as a Ben Graham Net Net which has returned 460% over the last 11 years). They may need a stock market oriented CEO who is prepared to do the things which creates the noise to get people interested, but in the meantime we have a results day plus hopefully an "Investor Meet Company" or similar following that. There was no liquidity for that £5k, so it is just available to private punters at this price. No guarantee at all of a long term win, but that doesn't have to matter. Could tank to 4p if they come with nothing to say. Read Full Thread Follow Reply
Posted at 11/4/2023 09:31 by mikemine1 TRLS seems to fit right in there with the Commission's view of the future. Well done Wan. Read Full Thread Follow Reply
Posted at 28/2/2023 10:11 by wan Well, do we assume that the delay of around 6 weeks in launching the D2C IBS offering (still ahead of the originally expected launch for IBS in H1 2023) has had a bearing on the delayed TU? Not to mention the progression to late-stage discussions with several pharma co.'s and patient services partners who deliver programs to pharmaceutical companies, is perhaps also taking longer, and I can see that some pharma's have an interest in addressing IBS (and IBD e.g. Takeda), and that a certain patient service partner covers IBS, but not IBD. I am trying to remain somewhat optimistic (but it's wearing thinner by the day) but in any regard, the share price performance since admission to AIM has been utterly uninspiring, and thus the management have a 'lot' to do to change that! Read Full Thread Follow Reply
Posted at 24/2/2023 14:47 by wan Idomeneo...I agree that the CEO is excellent. Certainly the share price performance appears to be reflecting disappointment, and not reporting as guided is clearly not helping matters. And lets face it, whilst the recent updates have been encouraging, none of them have been game changing, but they should nonetheless contribute positively this year. The increasing interest from pharmaceutical companies and the progression to late-stage discussions (with at least two), might change the dynamics if they can successfully conclude something material. Perhaps those discussions are taking longer, and they had hoped to include them as part of the detailed trading update, which in turn would imply they might be close to concluding? I also have my eye on larger entities in the healthcare space where partnering with Trellus in addressing chronic conditions (initially IBD & IBS), could make a good fit strategically (expanding to address other chronic conditions, and/or some already covered by those entities), especially given that Trellus Health is the first and only digital health company to offer a 'scientifically validated', personalised resilience-based self-management training program for people living with chronic conditions which has been proven to reduce unplanned hospitalizations by 94%. After the disappointingly slow progress to date though, and the market in a state of being very unforgiving, updates of only incremental progress will hardly be well received given the early stage Trellus is at. Read Full Thread Follow Reply
Posted at 24/2/2023 12:34 by idomeneo "The Company expects to provide a more detailed trading update by early February 2023." It's late February and so far nothing. CEO was saying on the 3rd October call that she had been "strategically insulated" but there would now be a lot more news flow and evidence of the financial benefits. Since October the best news has been the agreement with New York State-based health insurer to offer the Trellus IBD program to up to 50 of its members over a 12-month period. So they just need another 7020 more to break even. As far as I can tell nothing is happening with the b2c with the app which is surely where some money should be coming in. The downloads are negligible, so I don't see what will change to make this increase. In theory they the app is being pushed by the relevant IBD groups, but for whatever reason this is not translating into downloads (and therefore payments). If you are not being "sold" the Trellus System why would you choose it of your own volition? I'm really scratching my head with this one. The CEO appears competent and dynamic but it would appear that the company will need all the funding it has and more to get this off the ground. After the call I was expecting that before now there would have been at least one announcement in the vein of "we have signed up XYZ Insurance Scheme which covers 3 million people and they will offer it to their 9000 IBD clients" All we have so far is a trial, which doesn't sound like they have been able to sell what they do without the insurer checking it for themselves despite the clinical evidence. At a launch price of 40p: "The Company expects to generate initial revenue in 2021 through demonstration projects with healthcare payers in the New York City metropolitan area". So what happened to that? Why isn't that generating revenue now? Agreements and understandings mean nothing without a clear indication of the likely imminent revenue. Has anybody any evidence of better actual financial news? Wouldn't it have been better to have made an announcement explaining why they were delaying the promised early Feb update? Read Full Thread Follow Reply
Posted at 13/2/2023 07:55 by wan With today's news, that now completes 3 of contracts highlighted in Trellus' Half-year Report - Significant progress with advancing B2B2C model I am very pleased to report that, despite the longer lead times in the B2B2C contracting process as previously reported in December 2021, we have made significant progress in advancing a number of conversations with payers , such as regional and national health plans, employers, health systems, GI provider networks, and pharmaceutical companies. Whilst we have launched our D2C model, we remain focused on our B2B2C offering which provides better quality patient outcomes at lower costs to health plans and employers. We are in productive conversations with two health plans, having entered late-stage discussions with one and starting the due diligence process with another; we are in the final contracting phase for a New York Medicaid plan and we have two further contracts, one with a large NY State employer and the other with a NY State Provider to support members of a large NY labor union, which we expect to be signed soon. We are in late-stage discussions with two large pharmaceutical companies in the US, one for patient support services and another for clinical trials screening, and we are in ongoing discussions with two patient services partners who deliver programs to pharmaceutical companies as part of a centralized patient support hub. We believe that our methodology will help pharmaceutical companies to improve patient adherence behaviors, encourage customer loyalty and engagement, and support clinical trial screening. Success under our B2B2C model will see those organisations driving their own members to the Trellus platform. Expansion into Irritable Bowel Syndrome (IBS) for comprehensive GI solution hTTps://uk.advfn.com/stock-market/london/trellus-health-TRLS/share-news/Trellus-Health-PLC-Half-year-Report/89183079 Hopefully we will see continued execution in IBS expansion and the pharma discussions/contracts that were also referred to, not to mention "The Company expects to provide a more detailed trading update by early February 2023." Read Full Thread Follow Reply
Posted at 19/1/2023 08:53 by wan The market is still unimpressed with Trellus, despite some positive news flow and change etc, but the market obviously wants more than a just a positive backdrop in terms of prospects. To repeat: Investors should keep in mind that management expect that the two recently signed IBD contracts will contribute positively in 2023, plus there is the launch for IBS, which addresses a much larger healthcare population in the US (c. 30 m people) and is expected to start Q1 2023 offering patients a comprehensive GI solution covering both IBD and IBS. I don't expect that the reported pharma interest has dissipated either given the interest referred to, not to mention pharma's own interest in data management, drug discovery and clinical trial design etc. But the dynamics appear to be on the cusp of change with regard to pharma developments related to IBD. From the Trellus Health Half-year Report - "We are in late-stage discussions with two large pharmaceutical companies in the US, one for patient support services and another for clinical trials screening, and we are in ongoing discussions with two patient services partners who deliver programs to pharmaceutical companies as part of a centralized patient support hub. We believe that our methodology will help pharmaceutical companies to improve patient adherence behaviors, encourage customer loyalty and engagement, and support clinical trial screening. Success under our B2B2C model will see those organisations driving their own members to the Trellus platform." Pharmaceutical competition looks set to increase, which may increase the attention, and intensify the ongoing discussions with Trellus - January 17, 2023 Digesting 2022 and looking forward to 2023 in IBD therapeutics The past year has seen quite a few new developments in inflammatory bowel disease therapy. Other important developments to anticipate in 2023 include the introduction of as many as eight adalimumab biosimilars to the U.S. market, which almost certainly will drive the price of adalimumab down, and the potential approvals of subcutaneous Entyvio (vedolizumab, Takeda) and Inflectra (infliximab-dyyb, Celltrion) for the treatment of IBD. These therapeutics have already been approved in multiple other regions including Europe. It will be interesting to see what effect the availability of the adalimumab biosimilars and subcutaneous vedolizumab and infliximab-dyyb will have on treatment algorithms, especially if the cost differences are significant. I suspect it will take time for us to “digest” all these new developments, and the publication of real-world experiences with these new agents will help shape our clinical practice. Here’s looking to 2023! Full article - hTTps://www.healio.com/news/gastroenterology/20230106/digesting-2022-and-looking-forward-to-2023-in-ibd-therapeutics Food for thought: Dr. Dubinsky is co-founder and equity owner in a MiTest Health, which received a licensing fee from Takeda for CDPATH. Dr. Dubinsky has received compensation from both Takeda Pharmaceutical and Prometheus Laboratories as a consultant. In addition to Takeda, Dr. Dubinsky also serves as a paid consultant for other pharmaceutical companies that develop and/or manufacture treatments for inflammatory bowel disease (IBD). Dr. Dubinsky is co-founder and equity owner of two start-up companies involved in IBD healthcare, Trellus Health and GoDoRun. Read Full Thread Follow Reply
Posted at 06/12/2022 09:43 by wan Quiet here with the shares trading, by my estimate (cash at year-end in Dec equating to c10p per share), at a relatively small premium to expected cash levels and which provide a cash runway into 2025 which is based on managements conservative assumptions only. I note that Trellus has updated/revamped their website - hTTps://www.trellushealth.com/ Investors should keep in mind that management expect that the two recently signed IBD contracts will contribute positively in 2023, plus there is the launch for IBS, which addresses a much larger healthcare population in the US (c. 30 m people) and is expected to start Q1 2023 offering patients a comprehensive GI solution covering both IBD and IBS. I don't expect that the reported pharma interest has dissipated either given the interest referred to, not to mention pharma's own interest in data management, drug discovery and clinical trial design etc. A reminder - "We are in late-stage discussions with two large pharmaceutical companies in the US, one for patient support services and another for clinical trials screening, and we are in ongoing discussions with two patient services partners who deliver programs to pharmaceutical companies as part of a centralized patient support hub. We believe that our methodology will help pharmaceutical companies to improve patient adherence behaviors, encourage customer loyalty and engagement, and support clinical trial screening. Success under our B2B2C model will see those organisations driving their own members to the Trellus platform." hTTps://uk.advfn.com/stock-market/london/trellus-health-TRLS/share-news/Trellus-Health-PLC-Half-year-Report/89183079 Read Full Thread Follow Reply
Posted at 11/11/2022 07:29 by wan Medtech execs ‘rethink’ long-term strategies as care settings shift: Accenture report Published Nov. 10, 2022 Dive Brief: More than 75% of surveyed medtech executives expect expanding care settings and delivery models to “significantly re-orient their company’s long-term strategy.” Dive Insight: The COVID-19 pandemic accelerated shifts that were already underway in the industry, notably moves from in-person to virtual interactions and from hospital to ambulatory care centers. According to Accenture’s report, which is based on the survey and interviews with 30 digital health senior executives and C-suite leaders, the shift in where care happens is only just beginning. “We estimate that 80% to 90% of chronic and behavioral care can shift to virtual. It means that providers are able to work to the full extent of their medical training, rather than burning time on more menial tasks,” an unidentified executive at AdvaMed’s Digital Health Center of Excellence said in the report. The surveyed and interviewed executives expect to transform their businesses in response to the shifts in how care is delivered. While traditional products still account for most sales, the executives see the expansion of care to new settings as part of their growth strategies. Accenture cited the use of diagnostic tests at physician’s offices or at home, rather than at large hospital labs, as an example of the changes. Full article - hTTps://www.medtechdive.com/news/medtech-execs-to-rethink-strategies-changing-care-settings-Accenture/636217/ The above sits well with the recent news from Trellus - LONDON, U.K. AND NEW YORK, U.S. (19 October 2022): Trellus Health plc (AIM: TRLS), which is commercializing a scientifically validated, personalized resilience-driven self-management solution for chronic health conditions at their intersection with mental health, announces that the Trellus Resilience Training and Self-Management Solution for Inflammatory Bowel Disease (the "Trellus IBD program") is now available on GI OnDemand, gastroenterology's leading multidisciplinary virtual integrated care platform . GI OnDEMAND, a joint venture between the American College of Gastroenterology ("ACG") and Gastro Girl, Inc., now offers the Trellus IBD program, to all GI OnDEMAND and ACG members nationwide to coordinate and deliver personalized behavioral, emotional and nutritional support for their IBD patients remotely via digital solutions, and access to an expert resilience team via telehealth . The Trellus IBD program will be the only resilience driven self-management training solution offered via this platform to over 16,000 gastrointestinal ("GI") professionals across the US for the benefit of the millions of patients they collectively serve. hTTps://uk.advfn.com/stock-market/london/trellus-health-TRLS/share-news/Trellus-Health-PLC-Trellus-IBD-program-launches-on/89324962 Read Full Thread Follow Reply
Posted at 14/12/2021 10:43 by cambridgedon Thanks Wan. Seems that the RENX and TRls share prices are suffering at the same time! In one sense they both represent a lot lower risk than at the IPO/launch price but the recent falls have also got many to question what they are really worth. Thoughts? CD Read Full Thread Follow Reply

Trellus Health share price data is direct from the London Stock Exchange

Your Recent History

LSE

TRLS

Trellus He..

Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 | support@advfn.com

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US ADVFN Korea

V: D: 20230530 07:58:30